Ildong signs antibody deal with US firm

Published: 2012-11-19 06:56:00

Updated: 2012-11-19 06:56:00

Ildong Pharmaceutical said Thursday it has signed an exclusive licensing agreement with the U.S. based TG Therapeutics Inc. for the development and commercialization of the company's novel anti-CD20 antibody, Ublituximab (TGTX-1101) in Korea and seven countries in Southeast Asia.

Under the deal, TG Therapeutics will receive an upfront payment of $2 million in addition to sales based mileston...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.